Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in active psoriatic arthritis
NCT01989468Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2014
- Primary completion
- May 2015
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
A Phase 3 trial of secukinumab in psoriatic arthritis (PsA), sponsored by Novartis. Started Apr 2014; status: completed.
02
Drugs
secukinumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT01989468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01989468.